Holly Lewis, MD, PhD | Duke University - Segura Lab

Holly is working with MAP hydrogels, a three-dimensional scaffold with niches that facilitate immune remodeling of injured tissues. We've already shown that our MAP hydrogels can regenerate skin wounds with sebaceous glands, hair follicles, and improved tensile strength and barrier function - next up, improved transplantation tolerance.

<img src="https://seguralab.duke.edu/wp-content/uploads/2021/07/Holly_Lewis_c3.png" />

08 Jul Holly Lewis, MD, PhD

Senior Research Scientist

Posted at 21:38h in by Lindsay Riley

Engineering biomaterials, culturing tolerance: After completing a postdoctoral fellowship with Prof. Segura, Holly has remained part of the lab as a senior research scientist, while finishing her clinical training in Duke’s Plastic & Reconstructive Surgery program. As an aspiring surgeon-scientist, Holly’s research lab-within-a-lab is carried out thanks to broad support from the NIH, Duke and several talented scientists & mentees in the Segura Lab family. Her interests include tissue engineering, hand surgery and gender-affirming healthcare. She is a co-editor of the journal Advanced Biology on issues related to tissue engineering in transgender biology. Holly brings to the Segura Lab a breadth of clinical knowledge, including lymph node mapping, reconstructive surgery and transplantation. Lewis completed her MD and PhD at Emory, focusing on cellular immunology, chemical biology, and mesenchymal stem cell therapy. Holly pursued her undergraduate at Harvard, concentrating in Chemistry with a secondary field in Romance languages (Spanish, Portuguese, Catalan). Holly is an advocate for translational science in engineering & medicine: she has helped the lab launch partnerships with clinicians in Plastic Surgery, Immunology, Neurosurgery, Pathology and Transplant, as she aims to develop biomaterials for reconstructive surgery and transplant immunology.

Contact

Email: holly.lewis@duke.edu

Publications

Kloer C, Lewis HC, and Rezak K. “Delays in gender affirming healthcare due to COVID-19 are mitigated by expansion of telemedicine.” Am J Surg, September 23, 2022. https://doi.org/10.1016/j.amjsurg.2022.09.036.

Lewis HC, Hart AL, Fobare A, Styblo TM, Losken A. “Preoperative Body Image Factors Are Associated with Complications after Breast Reconstruction.” Plastic &Amp; Reconstructive Surgery 149, no. 3 (March 2022): 568–77. https://doi.org/10.1097/prs.0000000000008825.

Lewis HC, Cendales LC. “Vascularized composite allotransplantation in the United States: a retrospective analysis of OPTN data after five years of the Final Rule.” American Journal of Transplantation. 2020 Jun 2. 1-6. doi:10.1111/ajt.16086

Lewis HC, Chinnadurai R, Bosinger SE, Galipeau J. “The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cells.” Oncotarget 2017 Nov 3;8(54): 91914-91927

Oyoshi MK, He R, Kanaoka Y, ElKhal A, Kawamoto S, Lewis CN, Austen KF, Geha RS. “Eosinophil-derived Leukotriene C4 Signals via Type 2 Cysteinyl Leukotriene Receptor to Promote Skin Fibrosis in a Mouse Model of Atopic Dermatitis.” Proceedings of the National Academy of Sciences (USA). 2012. 109(13): 4992-7.